Multi-Omics Mendelian Randomization Results for IBS Drug Target Discovery

A 2026 study by Huiwen Ke integrated summary statistics from a large IBS genome-wide association study involving 53,400 cases and 433,201 controls with blood expression quantitative trait loci data. The analysis evaluated the causal effects of 5,642 potential druggable protein-coding genes on IBS risk, identifying EP300 and P2RY14 as promising candidate targets.

Use Cases

• Prioritizing genetically validated drug targets for IBS based on Mendelian randomization results
• Assessing potential on-target adverse effects for candidate genes using phenome-wide association study results
• Predicting therapeutic compounds for identified targets using molecular docking predictions
• Repurposing existing compounds like captopril and menadione for novel therapeutic pathways

Strengths

• Analysis integrates summary statistics from a large-scale GWAS with 53,400 cases and 433,201 controls
• Systematic evaluation of 5,642 potential druggable protein-coding genes
• Results validated with colocalization analysis and phenome-wide association study

Limitations

• Column-level documentation is absent; field semantics must be inferred after download
• Row count is unknown, which may limit suitability assessment
• The dataset is very small (10.2 KB), suggesting it contains summary results rather than raw data

Provenance

Source

figshare

Collection Method

Systematic druggable genome-wide Mendelian randomization analysis integrating GWAS and eQTL data

Freshness

Last updated 2026-05-18 22:02:53